Nurix Therapeutics Hits New 52-Week High of $24.86

Nurix Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 24.86 on June 30, 2026. This achievement marks a notable increase from its 52-week low of USD 8.20, reflecting a robust performance over the past year with a gain of 58.36%. The company, which currently holds a market capitalization of USD 1,518 million, has shown resilience in a competitive industry. Despite being loss-making, as indicated by its non-applicable price-to-earnings ratio, Nurix Therapeutics has managed to outperform the S&P 500, which recorded a 20.86% gain during the same period. Key financial metrics reveal a price-to-book ratio of 2.82, while the company operates with a debt-to-equity ratio of -1.10 and a return on equity of -49.09%. As Nurix Therapeutics continues to navigate the dynamic landscape of biotechnology, its recent price performance underscores its current market position and operational developments.